Huizenga Theodore Alan 4
4 · Ultragenyx Pharmaceutical Inc. · Filed Sep 5, 2024
Insider Transaction Report
Form 4
Huizenga Theodore Alan
SVP, Chief Accounting Officer
Transactions
- Sale
Common Stock
2024-09-03$56.19/sh−91$5,113→ 41,551 total
Footnotes (3)
- [F1]Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
- [F2]Includes 276 shares acquired under the Company's Amended and Restated 2014 Employee Stock Purchase Plan on April 30, 2024
- [F3]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.